Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2018 07:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Plan to Submit a New Drug Application (NDA) for Accelerated Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53

-- The Company met with the FDA Division of Neurology Products in February to obtain guidance on the regulatory pathway for golodirsen -- -- The Company intends to complete a rolling NDA submission...
March 01, 2018 16:01 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results and Recent Corporate Developments

-- Fourth quarter 2017 EXONDYS 51® (eteplirsen) total net revenues of $57.3 million -- -- Cash and investment balance of $1.1 billion as of December 31, 2017 -- CAMBRIDGE, Mass., March 01, 2018 ...
February 28, 2018 18:00 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
February 27, 2018 08:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
February 08, 2018 08:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Developments on March 1, 2018

CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
February 05, 2018 08:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
January 31, 2018 18:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
January 08, 2018 13:42 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Pre-Announces Fourth Quarter 2017 Revenue and Provides Full-Year 2018 Revenue Guidance for EXONDYS 51® (eteplirsen), Representing Approximately 100 Percent Year-over-Year Growth

-- Fourth quarter 2017 EXONDYS 51 unaudited revenue of $57.3 million -- -- Full-year 2017 EXONDYS 51 unaudited revenue of $154.6 million -- -- Full-year 2018 EXONDYS 51 revenue guidance of $295 –...
January 02, 2018 08:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
December 29, 2017 18:00 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...